Strongbridge Biopharma plc provided earnings guidance for the fourth quarter and full year ended December 31, 2019 and full year 2020. For the fourth quarter, the company expected net product sales of approximately $5.6 million.

For the year ended December 31, 2019, the company expected net product sales of approximately $21.7 million, exceeding its previous $18 to $20 million guidance range.

For the year 2020, the company expected revenue guidance will be approximately $26 to $27 million.